Fresh analysis indicates that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who stop conventional lifestyle programs.
Research printed in a prominent medical journal shows that while obese individuals frequently drop about a fifth of their body weight while using the jabs, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using these medications should be aware of the danger of quick rebound weight gain when the therapy ends," warns expert Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight within about 18 months.
Comparing Therapies
The analysis, which looked at dozens of trials involving thousands of participants, compared the outcomes of the injectable medications with older methods.
The team point out that individuals who shed pounds through diet and exercise typically have a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Regain
Doctors suggest the mechanism of the drugs accounts for the heightened weight return.
The injections copy a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the system to produce less of its own natural hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating far more likely."
A Chronic Issue?
Health authorities advise the jabs for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, due to the likelihood of weight regain, the therapy might need to be life-long.
This view is supported by pharmaceutical companies, who note that the results "underscore the chronic nature of excess weight," akin to managing conditions like diabetes.
Patient Testimonies
Individuals who have stopped the medication describe a intense resurgence of hunger.
"It was like a switch that goes on and you're instantly starving," said a patient.
This difficulty is exacerbated if individuals have not developed permanent dietary or behavioural changes during treatment.
Widespread Adoption
Figures indicate that a significant number of adults in the UK have used these injections in the past year, with interest being substantial.
- Use is more common among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent cure and long-term success likely depends on integrated lifestyle changes.
